Table 3. Predictors for reporting side effects after COVID-19 vaccination with Comirnaty, by multivariate analysis, Israel, December 2020–March 2021.

	First dose			Second dose
	AOR	95% CI	p value	AOR	95% CI	p value
Age (years)a	0.976	0.976–0.977	< 0.001	0.963	0.962–0.964	< 0.001
Sex
Male	Reference
Female	1.92	1.89–1.96	< 0.001	2.13	2.08–2.17	< 0.001
Comorbidities
No comorbidity	Reference
Immunosuppression	1.03	0.97–1.09	0.312	0.86	0.80–0.92	< 0.001
BMI > 35	1.18	1.13–1.23	< 0.001	0.96	0.92–1.01	0.096
Cancer	0.97	0.93–0.99	0.039	0.95	0.92–0.98	0.004
Diabetes	1.01	0.97–1.05	0.610	0.82	0.79–0.85	< 0.001
Pregnancy status	0.65	0.59–0.72	< 0.001	0.44	0.39–0.51	< 0.001

AOR: adjusted odds ratio; BMI: body mass index (kg/m²); CI: confidence interval; COVID-19: coronavirus disease.

^a Age was a continuous variable, increase or decrease per year.

Multivariate logistic regression model. Comorbidities and pregnancy status were identified from Maccabi Healthcare Services registries.